Neuralink company profile: valuation, funding & revenue

This Neuralink company profile covers the company's valuation, revenue, funding rounds, investors and history. Neuralink works in medical technology, with a focus on brain-computer interfaces. It was founded in 2016 and is headquartered in Fremont, California, United States. Its latest valuation on record is About US$9 billion pre-money (reported) (June 2025). Every figure links to a public source, and anything the company hasn't disclosed is marked as such.

Revenue

Funding history

Neuralink timeline

Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.

• 2016 — Neuralink is founded in Fremont by Elon Musk, Max Hodak, Dongjin Seo, Paul Merolla and others.
• 2023 — Series D: US$280M (plus a later US$43M tranche). Investors: Founders Fund (lead).
• Jun 2025 — Series E: US$650M, valuing the company at About US$9B pre-money (reported). Investors: ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, DFJ Growth, G42, Lightspeed, QIA, Valor Equity Partners, Vy Capital and others.
• June 2025 — Patients: Implanted in five people with severe paralysis at the time of the Series E.

Investors

Overview

Neuralink develops brain-computer interfaces: devices implanted in the brain that record neural activity and translate it into commands for computers and other devices. Its first product, called Telepathy, is designed to let people with severe paralysis control a computer cursor, type and use apps just by thinking. The company is also developing Blindsight, aimed at restoring a form of vision to people who are blind, and has spoken about longer-term goals of treating neurological conditions and eventually enhancing human abilities.

Neuralink was founded in 2016 by Elon Musk and a group of scientists and engineers including Max Hodak, Dongjin Seo and Paul Merolla. Musk has been its most prominent backer and public face. Several co-founders have since left; Hodak went on to found another brain-computer interface company, Science Corp. Neuralink is based in Fremont, California, with facilities in Austin, Texas.

How the device works

Neuralink's implant, called the N1, is a coin-sized device placed in the skull. Ultra-thin flexible threads carrying more than a thousand electrodes are inserted into the brain's motor cortex by a custom surgical robot designed to avoid blood vessels. The electrodes record the activity of neurons as a person intends to move, and software decodes those signals into actions such as moving a cursor. The device is wireless and recharges through the skin, so patients don't have wires coming out of their heads, an important practical difference from older research systems.

Clinical progress

Neuralink received approval from the US Food and Drug Administration to begin human trials in 2023 and implanted its first patient in early 2024. That patient, who is paralysed from the shoulders down, demonstrated controlling a computer, playing chess and video games, and browsing the internet using the implant. Early in the trial, some threads retracted from the brain, reducing performance, which the company addressed through software changes. By the time of its 2025 funding, Neuralink said it had implanted five people, and it has since expanded trials to more participants and to sites outside the US, including Canada, the UK and the UAE. The FDA granted breakthrough device designations for its speech restoration and Blindsight programmes, which can speed review.

Funding

• 2023, Series D: US$280 million led by Founders Fund, with a later US$43 million tranche.
• June 2025, Series E: US$650 million from investors including ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, DFJ Growth, G42, Lightspeed, the Qatar Investment Authority, Valor Equity Partners and Vy Capital. Semafor reported the round valued Neuralink at about US$9 billion before the investment.

Since then, secondary market estimates have varied widely, and reports have speculated about further funding, but we haven't confirmed a new priced round, so we use the 2025 figure.

Revenue and business model

Neuralink has no commercial product on the market and no meaningful revenue. Its path to revenue depends on regulatory approval of its devices, followed by reimbursement from insurers and health systems. Medical devices typically take many years to move from first human trials to approval, and brain implants face particularly high safety bars.

Competition

Neuralink competes with other brain-computer interface companies, including Synchron, which inserts its device through blood vessels without open brain surgery, Precision Neuroscience, Paradromics, Blackrock Neurotech and Science Corp. Academic research groups have demonstrated impressive results too, such as decoding speech from brain signals. Neuralink's advantages are its funding, its high-channel wireless implant and surgical robot, and its public profile.

Neuralink at a glance

Neuralink is a Fremont, California brain-computer interface company founded in 2016 by Elon Musk and a team of scientists. It began human trials in 2024 and had implanted five people with paralysis by June 2025, when it raised a US$650 million Series E reportedly at about US$9 billion pre-money from investors including ARK, Founders Fund and Sequoia. It has no commercial revenue yet.

Ethics and safety

Brain implants raise significant ethical questions: long-term safety of devices in the brain, informed consent from vulnerable patients, what happens if a company stops supporting an implanted device, and the privacy of neural data. Neuralink has also faced scrutiny over its animal testing practices, including federal inquiries. Regulators, ethicists and patient groups will continue to watch closely as trials expand.

Valuing a pre-revenue medtech company

Investors in Neuralink are betting on long-term potential: helping millions of people with paralysis, blindness, ALS and other conditions, and possibly much broader uses. The valuation reflects that potential, the company's technical progress and the profile of its founder, rather than near-term revenue. Our guide to pre-revenue valuation methods explains how such valuations are approached, and our guide to investing in pre-IPO companies covers the risks of secondary market prices.

Questions for observers

• How do outcomes compare across Neuralink and competitors in published data?
• How durable are implants over many years?
• What is the regulatory pathway and timeline to approval?

Peer-reviewed publications of trial results would allow much more rigorous comparison than company demonstrations and social media videos, and would help doctors and regulators judge the technology on equal terms with rivals. Several competitors have already published their results in leading medical journals.

Upcoming milestones

Watch expanded trial results, first Blindsight implants, regulatory submissions, new funding rounds and published clinical data.

For readers

Patients and families can follow trial recruitment for brain-computer interfaces. Founders can see how long and costly medical device development is. Investors should treat Neuralink as a long-term, high-risk bet without near-term revenue.

Latest developments (October 2026)

Neuralink has not announced a new funding round in 2026; its last primary round was a US$650 million Series E in 2025 at about US$9 billion pre-money. Business Insider reported that secondary-market trades in 2026 implied valuations of roughly US$29 billion to US$42 billion, according to IT Home, but those are not company-confirmed prices. Neuralink has continued expanding human trials of its brain implant.

Sources

Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.

1. TechCrunch